Oak Associates’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.4M | Sell |
81,776
-5,000
| -6% | -$700K | 0.77% | 33 |
|
|
2025
Q4 | $10.7M | Buy |
86,776
+1,605
| +2% | +$195K | 0.64% | 38 |
|
|
2025
Q3 | $9.45M | Sell |
85,171
-4,651
| -5% | -$529K | 0.58% | 38 |
|
|
2025
Q2 | $9.96M | Buy |
89,822
+7,499
| +9% | +$798K | 0.65% | 37 |
|
|
2025
Q1 | $9.22M | Sell |
82,323
-45
| -0.1% | -$4.64K | 0.69% | 39 |
|
|
2024
Q4 | $7.61M | Sell |
82,368
-737
| -0.9% | -$66.4K | 0.52% | 40 |
|
|
2024
Q3 | $6.97M | Buy |
83,105
+424
| +0.5% | +$32.4K | 0.47% | 45 |
|
|
2024
Q2 | $5.67M | Sell |
82,681
-902
| -1% | -$60.2K | 0.38% | 45 |
|
|
2024
Q1 | $6.12M | Sell |
83,583
-692
| -0.8% | -$53.2K | 0.42% | 46 |
|
|
2023
Q4 | $6.83M | Sell |
84,275
-503
| -0.6% | -$39.1K | 0.52% | 45 |
|
|
2023
Q3 | $6.35M | Sell |
84,778
-2,079
| -2% | -$160K | 0.53% | 43 |
|
|
2023
Q2 | $6.69M | Sell |
86,857
-31,868
| -27% | -$2.54M | 0.54% | 43 |
|
|
2023
Q1 | $9.85M | Sell |
118,725
-10,509
| -8% | -$870K | 0.81% | 38 |
|
|
2022
Q4 | $11.1M | Buy |
129,234
+2,741
| +2% | +$217K | 0.93% | 34 |
|
|
2022
Q3 | $7.8M | Buy |
126,493
+7,436
| +6% | +$469K | 0.66% | 39 |
|
|
2022
Q2 | $7.36M | Sell |
119,057
-1,609
| -1% | -$99.6K | 0.58% | 40 |
|
|
2022
Q1 | $7.17M | Sell |
120,666
-11,612
| -9% | -$742K | 0.44% | 45 |
|
|
2021
Q4 | $9.61M | Sell |
132,278
-3,777
| -3% | -$260K | 0.51% | 41 |
|
|
2021
Q3 | $9.5M | Buy |
136,055
+7
| +0% | +$492 | 0.54% | 44 |
|
|
2021
Q2 | $9.37M | Sell |
136,048
-2,181
| -2% | -$146K | 0.53% | 44 |
|
|
2021
Q1 | $8.93M | Buy |
138,229
+20,289
| +17% | +$1.31M | 0.53% | 43 |
|
|
2020
Q4 | $6.87M | Sell |
117,940
-180,120
| -60% | -$10.9M | 0.42% | 50 |
|
|
2020
Q3 | $18.8M | Sell |
298,060
-33,479
| -10% | -$2.32M | 1.26% | 25 |
|
|
2020
Q2 | $25.5M | Sell |
331,539
-4,114
| -1% | -$315K | 1.71% | 16 |
|
|
2020
Q1 | $25.1M | Buy |
335,653
+1,976
| +0.6% | +$137K | 2.06% | 14 |
|
|
2019
Q4 | $21.7M | Sell |
333,677
-11,086
| -3% | -$722K | 1.28% | 29 |
|
|
2019
Q3 | $21.9M | Buy |
344,763
+5,339
| +2% | +$349K | 1.35% | 26 |
|
|
2019
Q2 | $22.9M | Buy |
339,424
+523
| +0.2% | +$34.4K | 1.43% | 22 |
|
|
2019
Q1 | $22M | Buy |
338,901
+43,032
| +15% | +$2.86M | 1.35% | 26 |
|
|
2018
Q4 | $18.5M | Buy |
295,869
+61,375
| +26% | +$4.29M | 1.3% | 24 |
|
|
2018
Q3 | $18.1M | Buy |
234,494
+26,103
| +13% | +$1.97M | 1.11% | 29 |
|
|
2018
Q2 | $14.8M | Buy |
208,391
+8,491
| +4% | +$600K | 0.99% | 34 |
|
|
2018
Q1 | $15.1M | Buy |
199,900
+195,600
| +4,549% | +$15.5M | 1.05% | 32 |
|
|
2017
Q4 | $308K | Buy |
4,300
+1,715
| +66% | +$130K | 0.02% | 149 |
|
|
2017
Q3 | $209K | Buy |
+2,585
| New | +$198K | 0.02% | 158 |
|
Other funds holding GILD
VCM
VPM
Oak Associates's GILD Position: Q1 2026 in Review
Oak Associates reduced its Gilead Sciences (GILD) stake by 5.8% in Q1 2026, selling an estimated $700K and leaving 81,776 shares worth $11.4M. The position accounts for 0.77% of the portfolio, ranked #33.
Oak Associates first reported a position in GILD in Q3 2017 and has held it in 35 quarters since. The position peaked at $25.5M in Q2 2020. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Oak Associates held 81,776 shares of Gilead Sciences worth $11.4M as of Q1 2026.
- Oak Associates sold 5,000 Gilead Sciences shares in Q1 2026, an estimated $700K.
- Gilead Sciences made up 0.77% of Oak Associates's portfolio in Q1 2026, its #33 holding.
- Oak Associates first reported a position in Gilead Sciences in Q3 2017 and has held it in 35 quarters since.
- Oak Associates's Gilead Sciences position peaked at $25.5M in Q2 2020.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Oak Associates's 13F filing for Q1 2026, filed 14 May 2026.